NewAmsterdam Pharma CAO sells 65K shares after exercise
NewAmsterdam Pharma’s Chief Accounting Officer Louise Frederika Kooij reported an exercise-and-sell transaction in Ordinary Shares.
Rhea-AI Filing Summary
NewAmsterdam Pharma’s Chief Accounting Officer Louise Frederika Kooij reported an exercise-and-sell transaction in Ordinary Shares. On May 26, 2026, she exercised options to acquire a total of 65,000 shares at exercise prices of $10.00 and $10.90 per share.
That same day she completed an open-market sale of 65,000 Ordinary Shares at a weighted average price of $35.69, with individual trades ranging from $35.12 to $36.09 per share. After these transactions she directly holds 24,353 Ordinary Shares, including 22,000 shares subject to restricted stock unit awards that continue to vest over time.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 65,000 shares ($1.67M approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Kooij Louise Frederika
Role
Chief Accounting Officer
Sold
65,000 shs ($2.32M)
Approx. gross sale proceeds
$2.32M
Approx. exercise cost
$655K
Approx. pre-tax spread
$1.67M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (right to buy) | 60,000 | $0.00 | $0.00 |
| Exercise | Option (right to buy) | 5,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 60,000 | $10.00 | $600K |
| Exercise | Ordinary Shares | 5,000 | $10.90 | $55K |
| Sale | Ordinary Shares | 65,000 | $35.69 | $2.32M |
Holdings After Transaction:
Option (right to buy) — 148,149 contracts (Direct);
Ordinary Shares — 24,353 shares (Direct)
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.12 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- F2. Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
- F3. The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.
- F4. The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Key Figures
Shares sold: 65,000 shares
Weighted average sale price: $35.69 per share
Options exercised at $10.00: 60,000 shares
+3 more
6 metrics
Shares sold
65,000 shares
Open-market sale of Ordinary Shares on May 26, 2026
Weighted average sale price
$35.69 per share
Ordinary Shares sold in multiple trades, range $35.12–$36.09
Options exercised at $10.00
60,000 shares
Exercise of options with $10.00 exercise price on May 26, 2026
Options exercised at $10.90
5,000 shares
Exercise of options with $10.90 exercise price on May 26, 2026
Shares held after transactions
24,353 shares
Directly held Ordinary Shares following May 26, 2026 activity
Unvested RSU shares
22,000 shares
Ordinary Shares subject to restricted stock unit awards, still vesting
Key Terms
weighted average price, restricted stock unit, option (right to buy), Exercise or conversion of derivative security, +2 more
6 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock unit financial
"Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
option (right to buy) financial
"security_title: "Option (right to buy)" in the derivative transactions."
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security"."
open-market sale financial
"transaction_action: "open-market sale" for the Ordinary Shares disposition."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"shares underlying the option vest in equal monthly installments over four years."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did NewAmsterdam Pharma (NAMS) report for its CAO?
NewAmsterdam Pharma reported that Chief Accounting Officer Louise Frederika Kooij exercised options for 65,000 Ordinary Shares and sold 65,000 shares in an open-market transaction on May 26, 2026, reflecting an exercise-and-sell pattern while retaining a remaining equity stake.
What option exercises did the NewAmsterdam Pharma (NAMS) CAO report?
She reported exercising options covering 5,000 shares at a $10.90 exercise price and 60,000 shares at a $10.00 exercise price. These exercises converted derivative option positions into Ordinary Shares before the corresponding open-market sale transactions were completed.
What does the Form 4 say about the CAO’s restricted stock units in NewAmsterdam Pharma (NAMS)?
The filing notes that 22,000 Ordinary Shares are tied to restricted stock unit awards that are still subject to vesting. These RSUs represent potential future share delivery as the CAO continues to satisfy ongoing service-based vesting conditions with the company.
Were the NewAmsterdam Pharma (NAMS) CAO’s sales executed in one trade or multiple trades?
The sale price is reported as a weighted average, indicating multiple trades. The Form 4 explains that shares were sold in several transactions, with prices ranging from $35.12 to $36.09 per share on May 26, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
